Company news
Jiangsu Yahong Meditech Co., Ltd. news in 2026
Jiangsu Yahong Meditech Co., Ltd.'s news releases, calls and decks from 2026, newest first.
(688176)"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
October 28, 2026
(688176)"JIANGSU YAHONG MEDITECH CO., LTD."Report for Q3 2026
October 27, 2026
(688176)"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Voluntary Disclosure of Clinical Research Progress on APL-1702 Presented at the 38th Annual Meeting of the International Papillomavirus Society in 2026
October 22, 2026
(688176)"JIANGSU YAHONG MEDITECH CO., LTD."Notice on Convening the 1st Extraordinary General Meeting in 2026
October 12, 2026
(688176)"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Signing of a Conditional Exclusive License Agreement with Theramex
October 7, 2026
(688176)"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Resolutions of the Employees' Congress
September 29, 2026
(688176)"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Resolutions of the 25th Meeting of the 2nd Board of Directors
September 29, 2026
Announcement on Summary of the 2026 Employee Stock Ownership Plan (Draft)
September 29, 2026
Announcement on Voluntary Disclosure of Completion of First Subject Enrollment in the Phase I Clinical Trial of APL-2501
September 22, 2026
Announcement on Change of Core Technical Personnel
September 18, 2026
Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 8, 2026
Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026
August 28, 2026
Jiangsu Asieris Pharmaceuticals Co., Ltd.: Announcement on Voluntary Disclosure of APLD-2304 Obtaining EU CE Certification
August 27, 2026
Jiangsu Asieris Pharmaceuticals Co., Ltd.: Announcement on Voluntary Disclosure of the Approval of the Clinical Trial Application for APL-2501 by the National Medical Products Administration
August 26, 2026
Announcement on Voluntary Disclosure of the FDA Approval of the APL-2501 Clinical Trial Application
August 13, 2026
Announcement on Arbitration Progress and Submission of Counter‑claim in Arbitration
August 5, 2026
Announcement on Receipt of Arbitration Notice
July 23, 2026
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
June 23, 2026
Announcement on Adjustment of Key Technical Personnel
June 17, 2026
Announcement on Vesting Results of the 3rd Vesting Period of Those Initially Granted and the 2nd Vesting Period of Those Reserved for Grant in 2022 Restricted Stock Incentive Plan and Listing of Stocks
June 16, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 27, 2026
Announcement on Resignation of Securities Affairs Representative
May 22, 2026
Announcement on By-election of Directors
May 6, 2026
Announcement on Resolutions of the 22nd Meeting of the 2nd Board of Directors
April 29, 2026
Announcement on Requesting the General Meeting to Authorize the Board of Directors to Conduct Issuance of Shares to Specific Objects by Summary Procedure
April 17, 2026
Announcement on Resignation of Non-independent Director
March 27, 2026
Announcement on Abnormal Fluctuations in Stock Trading
March 6, 2026
Announcement on Voluntary Disclosure of Successful Acceptance of the Marketing Authorization Application for APL-1702 by the European Medicines Agency
February 27, 2026
Announcement on Expected Loss in Performance for 2025
January 30, 2026
Announcement on Voluntary Disclosure of Permission Granted by the Australian Authorities for the Initiation of Phase I Clinical Trials of APL-2401
January 22, 2026
Announcement on Using Partial Temporarily Idle Raised Funds for Cash Management
January 16, 2026
Announcement on Voluntary Disclosure of Completion of 1st Subject Enrollment in Phase 1 Clinical Trial of APL-2401
January 8, 2026